Novavax Historical Income Statement
| NVAX Stock | USD 8.72 0.10 1.16% |
Historical analysis of Novavax income statement accounts such as Total Revenue of 1 B can show how well Novavax performed in making a profits. Evaluating Novavax income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Novavax's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Novavax latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novavax is a good buy for the upcoming year.
Novavax |
About Novavax Income Statement Analysis
Novavax Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Novavax shareholders. The income statement also shows Novavax investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Novavax Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Novavax generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Novavax. It is also known as Novavax overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Novavax's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Reconciled Depreciation is fairly stable compared to the past year.
Novavax income statement Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (18.0M) | 4.9M | 12.7M | 29.1M | 41.2M | 43.3M | |
| Selling General Administrative | 34.4M | 145.3M | 298.4M | 488.7M | 475.4M | 499.1M | |
| Total Revenue | 18.7M | 475.6M | 1.1B | 1.6B | 983.7M | 1.0B | |
| Gross Profit | (95.2M) | 475.6M | 1.1B | 696.3M | 639.9M | 671.9M | |
| Other Operating Expenses | 148.3M | 892.3M | 2.8B | 2.2B | 1.6B | 1.6B | |
| Operating Income | (120.6M) | (416.7M) | (1.7B) | (644.7M) | (566.5M) | (538.2M) | |
| Ebit | (120.6M) | (416.7M) | (1.7B) | (633.8M) | (528.6M) | (502.2M) | |
| Research Development | 113.8M | 747.0M | 2.5B | 1.2B | 737.5M | 774.4M | |
| Ebitda | (138.6M) | (411.8M) | (1.7B) | (604.7M) | (487.4M) | (463.0M) | |
| Cost Of Revenue | 113.8M | 747.0M | 12.7M | 902.6M | 343.8M | 361.0M | |
| Total Operating Expenses | 148.3M | 892.3M | 2.8B | 1.3B | 779.1M | 818.1M | |
| Income Before Tax | (132.7M) | (418.3M) | (1.7B) | (653.6M) | (543.0M) | (515.9M) | |
| Total Other Income Expense Net | (12.1M) | (1.5M) | (28.0M) | (8.9M) | 23.5M | 24.7M | |
| Net Income | (130.1M) | (427.5M) | (1.7B) | (657.9M) | (545.1M) | (517.8M) | |
| Income Tax Expense | (2.6M) | 9.2M | 29.2M | 4.3M | 2.0M | 1.8M | |
| Net Income From Continuing Ops | (132.7M) | (418.3M) | (1.7B) | (657.9M) | (548.9M) | (576.4M) | |
| Non Operating Income Net Other | 2.8M | 1.5M | 13.6M | (6.8M) | (7.9M) | (7.5M) | |
| Net Income Applicable To Common Shares | (132.7M) | (418.3M) | (1.7B) | (657.9M) | (592.1M) | (562.5M) | |
| Reconciled Depreciation | 5.7M | 4.9M | 12.7M | 29.1M | 37.7M | 39.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.